A recent study has uncovered intriguing insights into the potential risks associated with GLP-1 use during pregnancy, shedding light on a previously understudied population. The research, published in JAMA, highlights the complexities surrounding the use of drugs like Ozempic, Wegovy, and Zepbound, which are known as glucagon-like peptide-1 receptor agonists (GLP-1s). These medications, designed to regulate weight and improve blood sugar, have been linked to numerous health benefits, including reduced risks of heart attack and blood clots. However, the study reveals a potential catch: stopping GLP-1s before conception may come with its own set of risks.
The study, conducted by researchers including Maya, focused on a specific group of women who had used GLP-1s between three years before and 90 days after conception. The findings indicate that those who had taken and then stopped GLP-1s faced an increased risk of preterm delivery, gestational diabetes, and hypertensive disorders of pregnancy. Additionally, the GLP-1-treated group gained more weight during pregnancy, with an average weight gain of 30 pounds (13.7 kilograms), compared to 23 pounds (10.5 kg) in the comparison group.
One of the study's key limitations is the comparison of people who had taken GLP-1s with those who had never used the medications but had similar body mass indices (BMIs). This approach may not fully capture the nuances of the treated group's experience, as their BMIs had likely decreased after starting the medication. To address this, the researchers plan to consider pre-GLP weights and find a comparison group with comparable baseline BMIs in future studies.
The commentary authors also highlight a potential contradiction with previous research. Some studies have suggested a lower risk of hypertensive disorders of pregnancy with GLP-1 use, but this may be attributed to a higher proportion of people prescribed GLP-1s for diabetes. The new study, however, focuses on individuals who took the medications specifically for obesity, which could explain the differing results.
Despite these findings, the commentary authors emphasize the need for further research to understand the medications' pros and cons for those planning to conceive. They advocate for generating evidence to inform obstetric care and guide treatment decisions, especially for vulnerable groups who were excluded from initial studies. The study serves as a crucial step in filling the knowledge gap, but more research is essential to provide comprehensive guidance on GLP-1 use before and during pregnancy.
